Bone marrow transplantation in acute leukemia

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Bone marrow transplantation (BMT) is a critical treatment for hematologic malignancies and aplastic anemia.
• Early BMT protocols faced challenges with graft-versus-host disease (GvHD) and opportunistic infections like cytomegalovirus (CMV).
• Strict gnotobiotic care and prophylactic measures were implemented to improve patient outcomes.

Purpose of the Study:

• To evaluate the outcomes of 142 bone marrow transplantations performed between 1975 and 1985.
• To assess the efficacy of cyclophosphamide-based conditioning regimens and GvHD prophylaxis.
• To analyze the incidence of GvHD and interstitial pneumonia in various hematologic conditions.

Main Methods:

• Conducted 142 bone marrow transplantations, with 74 cases involving acute leukemia.
• Utilized cyclophosphamide or cyclophosphamide with total body irradiation for conditioning.
• Administered intravenous CMV-hyperimmune globulin and CMV-negative blood products, with methotrexate for GvHD prophylaxis.
• Maintained patients under strict gnotobiotic conditions.

Main Results:

• Long-term survival was poor for acute leukemia in relapse (1/23).
• Survival rates were 55% for AML patients in first remission and 50% for ALL patients in remission.
• GvHD incidence varied: 28% in aplastic anemia, 26% in AML, 9% in ALL, and 63% in CML.
• Fatal interstitial pneumonia occurred in 34% of leukemia patients, but none in aplastic anemia patients.

Conclusions:

• BMT in first remission offers significant survival benefits for AML and ALL patients.
• GvHD and interstitial pneumonia remain critical complications post-transplantation, particularly in leukemia.
• Continued research into GvHD and infection prophylaxis is essential for improving BMT outcomes.